Jaktinib

DRUG11 trials

Conditions

Acute Graft vs Host DiseaseAlopecia AreataAnkylosing SpondylitisAtopic DermatitisCOVID-19 PneumoniaHealthy ParticipantsModerate-to-Severe Plaque PsoriasisMyelodysplastic Syndromes

Phase 1

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

TerminatedNCT04866056

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelodysplastic Syndromes, Myelofibrosis, Myeloproliferative Neoplasms

Start: 2021-09-30End: 2022-06-10Updated: 2022-12-01

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

CompletedNCT06193148

Suzhou Zelgen Biopharmaceuticals Co.,LtdHealthy Participants

Start: 2024-03-19End: 2024-06-18Updated: 2024-12-12

Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease

Not yet recruitingNCT07885228

Nanfang Hospital, Southern Medical UniversityAcute Graft vs Host Disease

Start: 2026-10-10End: 2028-06-10Target: 49Updated: 2026-10-21

Phase 2

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

CompletedNCT04539639

Suzhou Zelgen Biopharmaceuticals Co.,LtdAtopic Dermatitis

Start: 2020-12-02End: 2022-05-19Updated: 2023-03-24

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

CompletedNCT04612699

Suzhou Zelgen Biopharmaceuticals Co.,LtdModerate-to-Severe Plaque Psoriasis

Start: 2021-03-11End: 2022-08-15Updated: 2025-02-20

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

NCT05672888

First Affiliated Hospital of Zhejiang UniversityCOVID-19 Pneumonia

Start: 2023-03-31End: 2024-05-31Target: 60Updated: 2023-01-17

Phase 3

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

CompletedNCT04617028

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2021-02-05End: 2023-10-18Updated: 2023-11-13

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

CompletedNCT05051761

Suzhou Zelgen Biopharmaceuticals Co.,LtdAlopecia Areata

Start: 2021-09-04End: 2023-12-27Updated: 2025-03-14

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

CompletedNCT05255237

Suzhou Zelgen Biopharmaceuticals Co.,LtdAlopecia Areata

Start: 2022-03-25End: 2024-06-28Updated: 2025-03-18

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

CompletedNCT05861128

Suzhou Zelgen Biopharmaceuticals Co.,LtdAnkylosing Spondylitis

Start: 2023-11-10End: 2026-03-04Updated: 2026-09-24

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

CompletedNCT05861102

Suzhou Zelgen Biopharmaceuticals Co.,LtdAnkylosing Spondylitis

Start: 2023-07-20End: 2025-06-09Updated: 2026-09-22

Related Papers

An exploratory analysis of myelofibrosis (MF) patient subgroups by baseline hemoglobin levels in the gecacitinib phase 3 trial.

Journal of Clinical Oncology2025-05-28

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.

2024-12-18

A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).

Journal of Clinical Oncology2023-06-016 citations